We are fighting the "flench" affect.....with the BIIB, SAVA, CRTX and ANVS bad news, the buying public is hesitant to accept the good news/performance of AVXL. As said many times, it will take trial progress and the biotech sector response to such in order for the sp to climb significantly higher. Were we a bigger company with inroads to the press, IMHO we would see quicker movement. We will have to accept slower sp movement to remain a small but independent company. Common Sense!
Market Data 
Markets 
AI
